EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT)

Publication

EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT)

Journal Paper/Review - Aug 22, 2019

Kratochwil Clemens, Lassmann Michael, Mottaghy Felix M, Oyen Wim, Rahbar Kambiz, Schöder Heiko, Virgolini Irene, Wester Hans-Jürgen, Bodei Lisa, Fanti Stefano, Haberkorn Uwe, Kopka Klaus, Konijnenberg Mark, Kabasakal Levant, Fendler Wolfgang Peter, Eiber Matthias, Baum Richard, Bozkurt Murat Fani, Czernin Johannes, Delgado Bolton Roberto C, Ezziddin Samer, Forrer Flavio, Hicks Rodney J, Hope Thomas A, Herrmann Ken

Citation

Kratochwil C, Lassmann M, Mottaghy F, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester H, Bodei L, Fanti S, Haberkorn U, Kopka K, Konijnenberg M, Kabasakal L, Fendler W, Eiber M, Baum R, Bozkurt M, Czernin J, Delgado Bolton R, Ezziddin S, Forrer F, Hicks R, Hope T, Herrmann K. EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019; 46:2536-2544.

Type

Journal Paper/Review (English)

Journal

Eur J Nucl Med Mol Imaging 2019; 46

Publication Date

Aug 22, 2019

Issn Electronic

1619-7089

Pages

2536-2544

Brief description/objective

Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already become clinically accepted in several countries in- and outside Europe. PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (Lu-PSMA) is currently undergoing clinical validation. Retrospective observational data have documented favourable safety and striking clinical responses. Recent results from a prospective clinical trial (phase II) have been published confirming high response rates, low toxicity and reduction of pain in metastatic castration-resistant prostate cancer (mCRPC) patients who had progressed after conventional treatments. Such patients typically survive for periods less than 1.5 years. This has led some facilities to adopt compassionate or unproven use of this therapy, even in the absence of validation within a randomised-controlled trial. As a result, a consistent body of evidence exists to support efficacy and safety data of this treatment. The purpose of this guideline is to assist nuclear medicine specialists to deliver PSMA-RLT as an "unproven intervention in clinical practice", in accordance with the best currently available knowledge.